Galmed Pharmaceuticals entered into a Share Purchase Agreement on June 8, 2026, to acquire Colospan Ltd. The consideration consists of $2.5 million in cash and $2 million in Galmed ordinary shares, with an additional planned investment of at least $6 million over 24 months for commercial expansion.
